Dr. Edmund Tsui and author Dr. Douglas A. Jabs discuss the results of the ADVISE Trial, designed to compare adalimumab to conventional immunosuppressive drugs for the treatment of non-infectious intermediate, posterior, and panuveitides. From Dr. Jab's Ophthalmology article, "Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial."
Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial. Jabs, Douglas A. et al. Ophthalmology. In press.
Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html
